Details

Autor(en) / Beteiligte

• Orita, Noriaki
• Shimakami, Tetsuro
• Sunagozaka, Hajime
• Horii, Rika
• Nio, Kouki
• Terashima, Tekeshi
• Iida, Noriho
• Kitahara, Masaaki
• Takatori, Hajime
• Kawaguchi, Kazunori
• Kitamura, Kazuya
• Arai, Kuniaki
• Yamashita, Taro
• Sakai, Yoshio
• Yamashita, Tatsuya
• Mizukoshi, Eishiro
• Honda, Masao
• Kaneko, Shuichi

Titel

Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation

Ist Teil von

• Clinical journal of gastroenterology, 2019-02, Vol.12 (1), p.63-70

Ort / Verlag

Tokyo: Springer Japan

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• We report three cases of genotype 1b hepatitis C virus (HCV) reinfection after liver transplantation. When antiviral treatment was considered, all three patients had renal dysfunction and had been treated with immunosuppressive agents for a long time; one with tacrolimus (TAC) and the others with cyclosporine A (CyA). Therefore, the possible antiviral regimens among direct-acting antivirals (DAA) were limited and so we treated all three patients with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r). Because ritonavir is known to markedly increase the blood concentration of TAC and CyA through drug–drug interactions, close monitoring of blood concentrations of TAC or CyA and dose adjustments of immunosuppressive agents were needed. Sustained virus response was achieved in all the patients treated, and there were no adverse effects or transplant rejection. OBV/PTV/r might be a useful DAA regimen for patients with genotype 1 HCV reinfection in the setting of renal dysfunction.